Patterns of biologic agent utilization among patients with rheumatoid arthritis: A retrospective cohort study

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Ogale, Sarika ^a   Hitraya, Elena ^a   Henk, Henry J ^b  

^a GENENTECH INC   (United States)

^b OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIMALARIAL AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFUSION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT WITHDRAWAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; KAPLAN MEIER METHOD; MIDDLE AGED; TIME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 80052856528     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-204     Document Type: Article

References (41)

1. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL, J Rheumatol 2002 29 62 67 11824973 (Pubitemid 34041860)
2. Rheumatoid arthritis. Scott DL, Wolfe F, Huizinga TW, Lancet 2010 376 1094 1108 10.1016/S0140-6736(10)60826-4 20870100
3. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Scott DL, Smith C, Kingsley G, Clin Exp Rheumatol 2003 21 20 S27 14969046
4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van RP, Scholte M, Scott DL, Sokka T, Valesini G, van VR, Winthrop KL, Wong J, Zink A, van der HD, Ann Rheum Dis 2010 69 964 975 10.1136/ard.2009.126532 20444750
5. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, Burke F, Callaghan C, Candal-Couto J, Fokke C, Goodson N, Homer D, Jackman J, Jeffreson P, Oliver S, Reed M, Sanz L, Stableford Z, Taylor P, Todd N, Warburton L, Washbrook C, Wilkinson M, Rheumatology (Oxford) 2009 48 436 439 10.1093/rheumatology/ken450a
6. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, Fokke C, Goodson N, Jeffreson P, Lamb E, Mohammed R, Oliver S, Stableford Z, Walsh D, Washbrook C, Webb F, Rheumatology (Oxford) 2006 45 1167 1169 10.1093/rheumatology/kel215a (Pubitemid 44542111)
7. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002 46 328 346 11840435
8. Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. Meyer O, de BM, Berthelot JM, Cantagrel A, Combe B, Fautrel B, Flipo RM, Liote F, Maillefert JF, Saraux A, Wendling D, Guillemin F, X Le L, Joint Bone Spine 2007 74 73 78 10.1016/j.jbspin.2006.05.008 17194614 (Pubitemid 46240982)
9. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD, Clin Ther 2009 31 1871 1880 10.1016/j.clinthera.2009.08.020 19808146
10. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Yazici Y, Shi N, John A, Bull NYU Hosp Jt Dis 2008 66 77 85 18537774 (Pubitemid 351898370)
11. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Grijalva CG, Chung CP, Stein CM, Mitchel EF, Griffin MR, Rheumatology (Oxford) 2008 47 1061 1064 10.1093/rheumatology/ken193 (Pubitemid 351865934)
12. National Institute for Health and Clinical Excellence (NICE), NICE clinical guideline 79: Rheumatoid arthritis: the management of rheumatoid arthritis in adults. London 2009
13. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. http://www.rheumatology.org.uk/includes/documents/ cm-docs/2010/r/2-ra-guidelines-on-eligibility-criteria-for-the-first-biological- therapy.pdf
14. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA, Curr Med Res Opin 2006 22 169 183 10.1185/030079906X80341 16393443 (Pubitemid 43106920)
15. Health insurance portability and accountability act of 1996. Public law 104-191, 104th Congress. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw. pdf
16. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA, Med Care 2005 43 1130 1139 10.1097/01.mlr.0000182534.19832.83 16224307 (Pubitemid 41587600)
17. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. Gilbert TD, Smith D, Ollendorf DA, BMC Musculoskelet Disord 2004 5 36 10.1186/1471-2474-5-36 15485582 (Pubitemid 39532839)
18. Remicade prescribing information. Centocor Ortho Biotech Inc, Malvern, PA 2009
19. Orencia Prescribing Information. Bristol-Myers Squibb, Princeton, NJ 2009
20. Rituxan Prescribing Informatino. Genentech, South San Francisco, CA 2010
21. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P, Rheumatology (Oxford) 2008 47 507 513
22. The effectiveness of anti-TNF-{alpha} therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D, Rheumatology (Oxford) 2010 49 2313 2321 10.1093/rheumatology/keq169
23. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, Arthritis Rheum 2007 56 13 20 10.1002/art.22331 17195186 (Pubitemid 46106174)
24. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Gomez-Reino JJ, Carmona L, Arthritis Res Ther 2006 8 29 10.1186/ar1881 16507128
25. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Finckh A, Simard JF, Gabay C, Guerne PA, Ann Rheum Dis 2006 65 746 752 10.1136/ard.2005.045062 16339288 (Pubitemid 43799173)
26. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Caporali R, Sarzi-Puttini P, Atzeni F, Gorla R, Filippini M, Marchesoni A, Favalli EG, Bobbio-Pallavicini F, Montecucco C, Autoimmun Rev 2010 9 465 469 10.1016/j.autrev.2009.12.010 20044040
27. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Isaacs JD, Expert Opin Biol Ther 2009 9 1463 1475 10.1517/14712590903379494 19916731
28. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, Arthritis Rheum 2006 54 2793 2806 10.1002/art.22025 16947627 (Pubitemid 44497758)
29. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le BM, Dougados M, Ann Rheum Dis 2008 67 547 554 17921185 (Pubitemid 351498439)
30. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M, N Engl J Med 2005 353 1114 1123 10.1056/NEJMoa050524 16162882 (Pubitemid 41317434)
31. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Emery P, Keystone E, Tony HP, Cantagrel A, van VR, Sanchez A, Alecock E, Lee J, Kremer J, Ann Rheum Dis 2008 67 1516 1523 18625622
32. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C, Ann Rheum Dis 2010 69 387 393 10.1136/ard.2008.105064 19416802
33. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, Revaz S, Dudler J, Gabay C, Arthritis Rheum 2007 56 1417 1423 10.1002/art.22520 17469098 (Pubitemid 46764068)
34. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL, J Rheumatol 2009 36 2171 2177 10.3899/jrheum.090054 19723902
35. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Nair KV, Tang B, Van Den BJ, Zhang V, Saseen JJ, Naim A, Rahman M, Curr Med Res Opin 2009 25 303 314 10.1185/03007990802598736 19192975
36. The frequency and effectiveness of dose increase of adalimumab, etanercept and infliximab in daily clinical practice: results of the Dutch Rheumatoid Arthritis Monitoring registry. Blom M, Kievit W, Kuper H, Jansen T, Visser H, den Broeder A, Brus H, van de Laar M, van Riel P, Arthritis Care Res (Hoboken) 2010 62 1335 1341 10.1002/acr.20211
37. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Tang B, Rahman M, Waters HC, Callegari P, Clin Ther 2008 30 1375 1384 10.1016/S0149-2918(08)80063-X 18691998
38. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Ostergaard M, Arthritis Rheum 2010 62 22 32 10.1002/art.27227 20039405
39. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG, Ann N Y Acad Sci 2009 1173 837 846 10.1111/j.1749-6632.2009.04621.x 19758236
40. Enbrel prescribing information. Immunex Corporation, Thousand Oaks, CA 2010
41. Humira prescribing information. Abbott Laboratories, North Chicago, IL 2009